Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 48Methotrexate 33Cytarabine 27fludarabine 23fludarabine phosphate 22Rituximab 22Filgrastim 21Vincristine 19Busulfan 19Whole-Body Irradiation 18Mycophenolic Acid 18Dexamethasone 18Antilymphocyte Serum 17Cyclosporine 16Etoposide 15Tacrolimus 14Melphalan 14Calcium Dobesilate 14pegaspargase 12Peripheral Blood Stem Cell Transplantation 12Doxorubicin 12Radiotherapy 11Clofarabine 11Granulocyte Colony-Stimulating Factor 10Thiotepa 9Bortezomib 9thymoglobulin 8Dasatinib 8Asparaginase 8plerixafor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Precursor Cell Lymphoblastic Leukemia-Lymphoma × tozasertib × Clear all
NCT00500006 2015-01-30

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡